Unemployed women who begin taking GLP-1 weight-loss medications like Ozempic or Wegovy experience a 27% increase in their employment rate within 18 months, according to a working paper from the National Bureau of Economic Research (NBER). Harvard economist Rebecca Diamond, who analyzed survey data from over 10,000 adults, found that these gains appear tied to … Read more
Travelers using weight loss medications such as Ozempic, Wegovy, or Mounjaro must disclose their use to insurance providers to ensure coverage remains valid. The Association of British Insurers (ABI) warns that failing to declare prescribed medications or the underlying health conditions they treat can lead to invalidated policies and rejected claims, potentially leaving holidaymakers responsible … Read more
Pharmaceutical companies are racing to develop drugs that prevent muscle loss during weight reduction, addressing a critical side effect of GLP-1 medications like Ozempic and Zepbound. While current weight-loss drugs often cause patients to lose significant lean mass alongside fat, new candidates—including bimagrumab and Cambrian Biotech’s ATX-304—aim to prioritize metabolic health and muscle preservation, according … Read more
GLP-1 receptor agonists, such as semaglutide, appear to weaken the link between impulsive personality traits and violent behavior in current users, according to a study published in the journal Criminology. Researchers at Rutgers University found that the association between impulsivity and violence was 62% weaker in people currently taking these medications compared to those who … Read more
Colorado has secured federal authorization to import lower-cost prescription drugs from Canada, a move state officials estimate could save residents approximately $46 million on 20 common medications over three years. However, the program faces significant logistical hurdles, including Canadian export restrictions and private manufacturing contracts that currently prevent the sale of these drugs to the … Read more
Patients prescribed GLP-1 receptor agonists, such as semaglutide and tirzepatide, show a statistically significant decrease in daily physical activity after beginning treatment. Researchers from HSHS Saint John’s Hospital found that average daily step counts for users dropped from 5,047 to 4,487, while moderate-to-vigorous activity time declined by six minutes per day. These findings, scheduled for … Read more
Patients taking GLP-1 receptor agonists, such as Ozempic and Wegovy, are reporting unexpected improvements in ADHD symptoms, including increased focus, reduced procrastination, and better impulse control. While no clinical trials currently substantiate these claims, Dr. Lenard Adler, director of the Adult ADHD Program at NYU Langone Health, confirms he has observed these anecdotal reports among … Read more
The pharmaceutical landscape is undergoing a tectonic shift. While medications like Ozempic and Wegovy—collectively known as GLP-1 receptor agonists—have become household names for their efficacy in managing type 2 diabetes and obesity, a new frontier is emerging: the treatment of substance use disorders (SUDs). Emerging research suggests these drugs may do far more than manage … Read more
For years, the medical community has searched for a “silver bullet” to address the growing obesity epidemic. While no single solution exists, new data suggests we may be witnessing a historic turning point. A massive shift in how Americans manage their health—driven by the rapid adoption of GLP-1 medications like semaglutide—is finally moving the needle … Read more
The Weight-Loss Revolution: How Biotech is Rewriting Global Health Driving through the quiet, rolling farmland of Dunderrow, Ireland, you would never guess you are approaching the epicenter of a global medical revolution. Yet, hidden within Eli Lilly’s sprawling 50-hectare campus, the future of human health is being manufactured at an unprecedented scale. View this post … Read more